Laden...
| This week's FierceBiotech is brought to you by Hanson Wade. |
| 2020 is set to be a pivotal year for the gene therapy field. Multiple late-stage programs are on the brink of approval and existing infrastructure is being tested to breaking point as academic promise is transformed into large-scale commercial reality. Donât just speculate about how payers and groups like ICER evaluate gene therapies, learn directly from them and ask your burning questions to Harvard Pilgrim Healthcare Institute, ICER, Blue Cross Blue Shield and MIT NEWDIGS In-Depth Immunogenicity & Re-Dosing Insights Address the elephant in the room and prepare yourself for future re-dosing challenges by exploring the novel approaches Spark Therapeutics, Selecta Biosciences and the University of Florida are developing Insights into Large-Scale Manufacturing & Gene Therapy Facilities Ensure your process development approach is scalable and that you have appropriate facilities to handle large-scale manufacturing by learning from Pfizer, BioMarin and Sanofi Gain the International Regulatory Perspective Align your gene therapy development work with the actual requirements of the FDA and CFDA, to streamline your approach while ensuring regulatory work is robust This Friday, January 24 is your last chance to save up to $600 on your ticket for the meeting â secure your place now. |
| Want to reach 137,000+ FierceBiotech subscribers with your own message?
FierceMarkets, a division of Questex, LLC |
Laden...
Laden...
© 2024
